Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine XR augmentation after ECT remission in major depressive disorder
ACTRN12610000937011Phase 4Withdrawn
- Sponsor
- St Vincent's Hospital
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of quetiapine in major depressive disorder (MDD) (2 arms), sponsored by St Vincent's Hospital. Primary endpoints: Hamilton Depression Rating Scale score and Depressive relapse by HAMD. Planned start Mar 2011; status: withdrawn.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12610000937011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000937011.